<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-id journal-id-type="pmc">brjcancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">9310247</article-id><article-id pub-id-type="pmc">2228041</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>A pilot study of megestrol acetate and ibuprofen in the treatment of cachexia in gastrointestinal cancer patients.</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>McMillan</surname><given-names>D. C.</given-names></name></contrib><contrib contrib-type="author"><name><surname>O'Gorman</surname><given-names>P.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Fearon</surname><given-names>K. C.</given-names></name></contrib><contrib contrib-type="author"><name><surname>McArdle</surname><given-names>C. S.</given-names></name></contrib></contrib-group><aff>University Department of Surgery, Royal Infirmary, Glasgow, UK.</aff><pub-date pub-type="ppub"><year>1997</year></pub-date><volume>76</volume><issue>6</issue><fpage>788</fpage><lpage>790</lpage><abstract><p>Advanced gastrointestinal cancer patients with weight loss and an acute-phase response (n = 15) were given megestrol acetate (480 mg day(-1)) and ibuprofen (1200 mg day(-1)) for 6 weeks. Overall, there was an increase in body weight (P = 0.01) and a reduction in C-reactive protein concentrations (P = 0.02), with no change in total body water (P = 0.24) over this period. This regimen may be an effective non-toxic treatment for cancer cachexia and is worthy of further study.</p></abstract></article-meta></front><body><supplementary-material content-type="scanned-pages"><graphic xlink:href="brjcancer00170-0104.tif" xlink:title="scanned-page" xlink:role="788" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00170-0105.tif" xlink:title="scanned-page" xlink:role="789" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00170-0106.tif" xlink:title="scanned-page" xlink:role="790" mimetype="image" mime-subtype="tiff"/></supplementary-material></body></article>

